All the news Showing 10 of 87 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Why fatty liver disease could be the next public health crisis Daily Telegraph / 25 September 2019 Non-alcoholic fatty liver disease raises the risk of cancer in overweight people Keith Alcorn / 24 September 2019 Obesity without non-alcoholic fatty liver disease (NAFLD) does not raise the risk of cancer, but people with NAFLD who are also obese are almost twice as likely to be diagnosed with cancer ... Fatty liver raises the risk of death in people with HIV and hepatitis C Keith Alcorn / 15 September 2019 People with HIV and hepatitis C co-infection who had fatty liver disease were twice as likely to die during a five-year follow-up period as their counterparts without fatty liver disease, ... Gilead experimental NASH drug fails another study Reuters / 29 April 2019 Emricasan misses study endpoint for improving portal hypertension in people with NASH Liz Highleyman / 24 April 2019 The experimental caspase inhibitor emricasan did not meet the statistical threshold for improvement of portal hypertension in people with non-alcoholic steatohepatitis (NASH), but it did appear to have some benefit for those at ... NAFLD a rising cause of liver disease in people with HIV Liz Highleyman / 23 April 2019 Now that hepatitis C can be successfully treated, non-alcoholic fatty liver disease (NAFLD) is becoming an increasingly important cause of serious liver problems and liver-related death among people living with HIV in the ... Hepatic Steatosis Highly Prevalent in Young Adults With Lifelong HIV Infectious Disease Advisor / 17 April 2019 Obeticholic acid improves liver fibrosis in people with NASH Liz Highleyman / 12 April 2019 Obeticholic acid (Ocaliva) led to a significant improvement in liver fibrosis related to non-alcoholic steatohepatitis (NASH), offering a potential future option for an increasingly common liver disease with no good current therapies, researchers ... Experts warn of fatty liver disease 'epidemic' in young people The Guardian / 12 April 2019 Second-generation thiazolidinedione, MSDC-0602K may significantly improve liver enzymes, fibrosis, and glycaemic markers with minimal adverse events, according to a Phase 2b study EASL / 12 April 2019 ← Prev1...34567...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD NASH Experimental treatments for NASH/NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive